TY - JOUR
T1 - A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers
AU - Zoberi, Imran
AU - Wasserman, Todd H.
AU - Chao, K. S.Clifford
PY - 2002
Y1 - 2002
N2 - The daily administration of subcutaneous amifostine to patients with head and neck cancers before each radiation fraction may reduce the long-term incidence of hypothyroidism (HT) after radiotherapy to the neck and may provide an additional indication for amifostine (Ethyol) use. Cancers of the head and neck afflict 40,000 patients yearly in the United States, and radiotherapy plays a pivotal role in the management of at least half of these patients. Patients commonly are treated with radiation alone, combined surgery and radiation, or definitive chemoradiotherapy. Local control of disease is achieved in many patients who are at risk for late sequelae of treatment that may diminish quality of life.
AB - The daily administration of subcutaneous amifostine to patients with head and neck cancers before each radiation fraction may reduce the long-term incidence of hypothyroidism (HT) after radiotherapy to the neck and may provide an additional indication for amifostine (Ethyol) use. Cancers of the head and neck afflict 40,000 patients yearly in the United States, and radiotherapy plays a pivotal role in the management of at least half of these patients. Patients commonly are treated with radiation alone, combined surgery and radiation, or definitive chemoradiotherapy. Local control of disease is achieved in many patients who are at risk for late sequelae of treatment that may diminish quality of life.
UR - http://www.scopus.com/inward/record.url?scp=0036128223&partnerID=8YFLogxK
U2 - 10.1053/srao.2002.31357
DO - 10.1053/srao.2002.31357
M3 - Article
C2 - 11917278
AN - SCOPUS:0036128223
SN - 1053-4296
VL - 12
SP - 14
EP - 17
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 1 SUPPL. 1
ER -